Suppr超能文献

遗传性出血性疾病:血小板黏附和聚集障碍。

Inherited bleeding disorders: disorders of platelet adhesion and aggregation.

作者信息

Ramasamy Indra

机构信息

Department of Chemical Pathology, Newham General Hospital, Glen Road, London E13 8RU, UK.

出版信息

Crit Rev Oncol Hematol. 2004 Jan;49(1):1-35. doi: 10.1016/s1040-8428(03)00117-3.

Abstract

Platelet aggregation at sites of vascular injury is essential for the formation of the primary haemostatic plug. The mechanism of platelet aggregation under conditions of physiological flow is a complex multistep process, which requires the synergistic action of several different platelet receptors. Platelet interaction with collagen at sites of damage to the vascular endothelium involves adhesion, activation, secretion of platelet granular contents and finally aggregation. Other agonists other than collagen, such as fibrinogen, vWF and soluble agonists released from activated platelets (thromboxane A2 (TXA2) and ADP) are involved in platelet aggregation. Platelets express a variety of receptors including GP Ib-IX-V, GP VI, GP Ia-IIa and GP IIb-IIIa. One aspect of this complexity of function is the variety of inherited defects of platelet function. Hereditary disorders of platelet adhesion are Bernard-Soulier syndrome and von Willebrand disease. Glanzmann thrombasthenia is an inherited disorder of platelet aggregation. The application of molecular biology to the study of platelet disorders has identified defects in other collagen receptors, ADP receptors and TXA2 receptors. Defects affecting TXA2 production, the generation of procoagulant activity and secretion from dense bodies and alpha-granules are also encountered. Other rare diseases, Chediak-Higashi, Hermansky-Pudlak and Wiskott-Aldrich syndrome also affect platelet storage granules. In this article, recent advances in the understanding of platelet function and knowledge of inherited disorders that affect platelet adhesion and aggregation is reviewed. As progress advances towards individualisation of therapy the phenotypic bleeding tendency of each patient becomes relevant.

摘要

血管损伤部位的血小板聚集对于初级止血栓的形成至关重要。在生理血流条件下,血小板聚集的机制是一个复杂的多步骤过程,需要几种不同血小板受体的协同作用。血小板在血管内皮损伤部位与胶原的相互作用涉及黏附、激活、血小板颗粒内容物的分泌以及最终的聚集。除胶原外的其他激动剂,如纤维蛋白原、血管性血友病因子(vWF)以及活化血小板释放的可溶性激动剂(血栓素A2(TXA2)和二磷酸腺苷(ADP))也参与血小板聚集。血小板表达多种受体,包括糖蛋白(GP)Ib-IX-V、GP VI、GP Ia-IIa和GP IIb-IIIa。这种功能复杂性的一个方面是血小板功能的各种遗传性缺陷。血小板黏附的遗传性疾病有伯纳德-苏利综合征和血管性血友病。血小板无力症是一种血小板聚集的遗传性疾病。分子生物学在血小板疾病研究中的应用已确定了其他胶原受体、ADP受体和TXA2受体的缺陷。还发现了影响TXA2生成、促凝活性产生以及致密体和α颗粒分泌的缺陷。其他罕见疾病,如切迪阿克-东综合征、赫尔曼斯基-普德拉克综合征和维斯科特-奥尔德里奇综合征也会影响血小板储存颗粒。本文综述了对血小板功能理解的最新进展以及影响血小板黏附和聚集的遗传性疾病的相关知识。随着治疗个体化的进展,每位患者的表型出血倾向变得至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验